Original Research

DOI: 10.4244/EIJ-D-24-00897

One- versus three-month DAPT after everolimus-eluting stent implantation in diabetic patients at high bleeding risk: results from the XIENCE Short DAPT programme

Angelo Oliva1,2, MD; Dominick J. Angiolillo3, MD, PhD; Marco Valgimigli4,5, MD, PhD; Davide Cao1,2, MD; Samantha Sartori1, PhD; Sripal Bangalore6, MD, MHA; Deepak L. Bhatt1, MD, MPH, MBA; Gianluca Campo7, MD; Bassem M. Chehab8, MD; James W. Choi9,10, MD; Jose M. de la Torre Hernandez11, MD, PhD; Yihan Feng1, MS; Junbo Ge12, MD; Mauro Gitto1,2, MD; James Hermiller13, MD; Mitchell W. Krucoff14, MD; Vijay Kunadian15, MD; Raj R. Makkar16, MD; Aziz Maksoud17, MD; Franz-Josef Neumann18, MD; Hector Picon19, MD; Shigeru Saito20, MD; Gennaro Sardella21, MD; Holger Thiele22, MD; Ralph Toelg23,24, MD; Olivier Varenne25, MD, PhD; Birgit Vogel1, MD; Pascal Vranckx26, MD; Stephan Windecker27, MD; Roxana Mehran1, MD

Abstract

Background: In patients with diabetes mellitus (DM) and high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI), the optimal duration of dual antiplatelet therapy (DAPT) remains uncertain.

Aims: We sought to compare early DAPT discontinuation in DM and non-DM patients enrolled in the prospective XIENCE Short DAPT programme.

Methods: The effects of 1- versus 3-month DAPT on ischaemic and bleeding outcomes were compared using propensity score stratification. The primary endpoint was a composite of all-cause death or myocardial infarction (MI) at 1 year. The incidence of Bleeding Academic Research Consortium (BARC) Type 2 to 5 bleeding was the key secondary endpoint.

Results: Out of 3,352 included patients, 1,299 (38.8%) had DM; diabetic patients had a higher 1-year incidence of death or MI (DM vs non-DM: 10.1% vs 6.6%) and similar BARC 2-5 bleeding (DM vs non-DM: 9.5% vs 9.2%). With 1- versus 3-month DAPT, the incidence of death or MI did not statistically differ in DM patients (adjusted hazard ratio [adjHR] 0.70, 95% confidence interval [CI]: 0.47-1.05) and non-DM patients (adjHR 1.26, 95% CI: 0.87-1.81), although heterogeneity by DM status was evident (p for interaction=0.015). BARC 2-5 bleeding was numerically lower with 1-month DAPT in both groups (DM: adjHR 0.67, 95% CI: 0.45-1.01; non-DM: adjHR 0.78, 95% CI: 0.56-1.07; p for interaction=0.973).

Conclusions: Among HBR patients with DM undergoing PCI, 1-month DAPT, as compared to 3-month DAPT, was not associated with an excess of fatal or non-fatal MI and even reduced the occurrence of bleeding. These findings should be interpreted in the context of a predominantly stable patient population with low procedural complexity and may not be generalisable to higher-risk cases.

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 12
Jun 16, 2025
Volume 21 Number 12
View full issue


Key metrics

Suggested by Cory

Flashlight

10.4244/EIJ-D-24-00678 Jan 20, 2025
Late coronary embolisation after transcatheter aortic valve implantation
Ene C et al
Trending articles
172.05

Focus article

10.4244/EIJY19M08_01 Jan 17, 2020
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
Glikson M et al
free
42

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
26.5

Expert Review

10.4244/EIJ-D-24-00535 May 5, 2025
Catheter-based techniques for pulmonary embolism treatment
Costa F et al
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved